Drug Profile
Formoterol dry-powder inhalation - Novartis
Alternative Names: Eformoterol dry-powder inhalation - Novartis; Foradil Aerolizer; Foradile Aerolizer; Formoterol fumarate dry-powder inhalation - NovartisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 May 2003 A pharmacoeconomic study has been added to the Respiratory Tract Disorders therapeutic trials section
- 18 Mar 2003 Data presented at the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Asthma therapeutic trials section
- 06 Nov 2002 Foradil® Aerolizer® has been licensed to Schering-Plough in the USA